Drug Approval | July 23, 2024
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
Subscribe To Our Newsletter & Stay Updated
